Cameron R. MacDonald
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cameron R. MacDonald has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth A. Repasky
Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, USA
4 shared publications - Hemn Mohammadpour
Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
4 shared publications - Anurag K. Singh
Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York
1 shared publication Bonnie Hylander
Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States
1 shared publication- Bonnie L. Hylander
Department of OB/Gyn -Residency Program, Upstate University Hospital, Syracuse, New York
1 shared publication Christopher Gordon
5018 Butternut Rd, Durham, NC 27707, United States
1 shared publication
Latest Publications
- Open Access
- 2 June 2022
- Published by Wiley in Advanced Biology
- Vol. 6 (9) , e2200031
Circadian Rhythm Disruption Increases Tumor Growth Rate and Accumulation of Myeloid‐Derived Suppressor Cells
Circadian rhythm disruption is implicated in the initiation and progression of many diseases, including cancer. External stimuli, such as sunlight, serve to synchronize physiological processes and cellular functions to a 24‐h cycle. The immune system is controlled by circadian rhythms, and perturbation of these rhythms can potentially alter the immune response to infections and tumors. The effect of circadian rhythm disruption on the immune response to tumors remains unclear. Specifically, the effects of circadian disruption (CD) on immunosuppressive cell types within the tumor, such as myeloid‐derived suppressor cells (MDSCs), are unknown. In this study, a shifting lighting schedule is used to disrupt the circadian rhythm of mice. After acclimation to lighting schedules, mice are inoculated with 4T1 or B16‐F10 tumors. Tumor growth is increased in mice housed under circadian disrupting lighting conditions compared to standard lighting conditions. Analysis of immune populations within the spleen and tumor shows an increased accumulation of MDSCs within these tissues, suggesting that MDSC mediated immunosuppression plays a role in the enhanced tumor growth caused by circadian disruption. This paves the way for future studies of the effects of CD on immunosuppression in cancer.
- 2 June 2022
- Published by Wiley in Advanced Biology
- Vol. 6 (9) , e2200031
Open AccessCircadian Rhythm Disruption Increases Tumor Growth Rate and Accumulation of Myeloid‐Derived Suppressor Cells
Circadian rhythm disruption is implicated in the initiation and progression of many diseases, including cancer. External stimuli, such as sunlight, serve to synchronize physiological processes and cellular functions to a 24‐h cycle. The immune system is controlled by circadian rhythms, and perturbation of these rhythms can potentially alter the immune response to infections and tumors. The effect of circadian rhythm disruption on the immune response to tumors remains unclear. Specifically, the effects of circadian disruption (CD) on immunosuppressive cell types within the tumor, such as myeloid‐derived suppressor cells (MDSCs), are unknown. In this study, a shifting lighting schedule is used to disrupt the circadian rhythm of mice. After acclimation to lighting schedules, mice are inoculated with 4T1 or B16‐F10 tumors. Tumor growth is increased in mice housed under circadian disrupting lighting conditions compared to standard lighting conditions. Analysis of immune populations within the spleen and tumor shows an increased accumulation of MDSCs within these tissues, suggesting that MDSC mediated immunosuppression plays a role in the enhanced tumor growth caused by circadian disruption. This paves the way for future studies of the effects of CD on immunosuppression in cancer.
- Open Access
- 1 October 2021
- Published by Elsevier in Cell Reports
- Vol. 37 (4) , 109883
β2-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME
- 1 October 2021
- Published by Elsevier in Cell Reports
- Vol. 37 (4) , 109883
Open Accessβ2-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME
- Open Access
- 23 April 2021
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 27 (3) , 187-197
Psychosocial stress and immunosuppression in cancer: what can we learn from new research?
SUMMARY: It is generally believed that the physiological consequences of stress could contribute to poor outcomes for patients being treated for cancer. However, despite preclinical and clinical evidence suggesting that stress promotes increased cancer-related mortality, a comprehensive understanding of the mechanisms involved in mediating these effects does not yet exist. We reviewed 47 clinical studies published between 2007 and 2020 to determine whether psychosocial stress affects clinical outcomes in cancer: 6.4% of studies showed a protective effect; 44.6% showed a harmful effect; 48.9% showed no association. These data suggest that psychosocial stress could affect cancer incidence and/or mortality, but the association is unclear. To shed light on this potentially important relationship, objective biomarkers of stress are needed to more accurately evaluate levels of stress and its downstream effects. As a potential candidate, the neuroendocrine signalling pathways initiated by stress are known to affect anti-tumour immune cells, and here we summarise how this may promote an immunosuppressive, pro-tumour microenvironment. Further research must be done to understand the relationships between stress and immunity to more accurately measure how stress affects cancer progression and outcome.
- 23 April 2021
- Published by Royal College of Psychiatrists in BJPsych Advances
- Vol. 27 (3) , 187-197
Open AccessPsychosocial stress and immunosuppression in cancer: what can we learn from new research?
SUMMARY: It is generally believed that the physiological consequences of stress could contribute to poor outcomes for patients being treated for cancer. However, despite preclinical and clinical evidence suggesting that stress promotes increased cancer-related mortality, a comprehensive understanding of the mechanisms involved in mediating these effects does not yet exist. We reviewed 47 clinical studies published between 2007 and 2020 to determine whether psychosocial stress affects clinical outcomes in cancer: 6.4% of studies showed a protective effect; 44.6% showed a harmful effect; 48.9% showed no association. These data suggest that psychosocial stress could affect cancer incidence and/or mortality, but the association is unclear. To shed light on this potentially important relationship, objective biomarkers of stress are needed to more accurately evaluate levels of stress and its downstream effects. As a potential candidate, the neuroendocrine signalling pathways initiated by stress are known to affect anti-tumour immune cells, and here we summarise how this may promote an immunosuppressive, pro-tumour microenvironment. Further research must be done to understand the relationships between stress and immunity to more accurately measure how stress affects cancer progression and outcome.
- Open Access
- 1 March 2021
- Published by Elsevier in Cellular Immunology
- Vol. 361, 104285
Comparing thermal stress reduction strategies that influence MDSC accumulation in tumor bearing mice
- 1 March 2021
- Published by Elsevier in Cellular Immunology
- Vol. 361, 104285
Open AccessComparing thermal stress reduction strategies that influence MDSC accumulation in tumor bearing mice